Discovery Stage

Build Compliance into Innovation

Start your compliance journey from Day 1. Validate AI models in target identification, ensure GxP-compliant preclinical data, and secure patient-derived data—all while maintaining the speed of innovation.

The Discovery Compliance Challenge

Preclinical data isn't GxP-compliant, AI models lack regulatory documentation

In the discovery stage, companies face a critical challenge: balancing innovation speed with regulatory readiness. AI models used in target identification and lead optimization often lack proper validation documentation. Preclinical data may not meet GxP standards, creating downstream compliance gaps that delay clinical development. Patient-derived data requires secure governance from the start, but traditional approaches add complexity and slow innovation.

tfives Discovery Solutions

ComplianceIQ

Validate AI models in target identification against 156 regulatory standards. Ensure your AI-driven discovery tools meet FDA, EMA, and ICH requirements from the start.

  • AI model validation documentation
  • Regulatory standard compliance checks
  • Audit-ready AI documentation

ClinoxisCore

GxP data management from Day 1. Establish compliant data workflows, validation protocols, and documentation standards that carry through your entire product lifecycle.

  • GxP-compliant data capture
  • Automated validation workflows
  • End-to-end data traceability

DataGovernanceIQ

Secure patient-derived data with enterprise-grade governance. Implement privacy controls, access management, and compliance frameworks from discovery through commercialization.

  • HIPAA/GDPR compliance
  • Secure data access controls
  • Patient privacy protection

Key Outcomes

AI Models Validated

Against 156 regulatory standards, ensuring your AI-driven discovery tools are audit-ready from Day 1

Full GxP Compliance

Preclinical data that meets regulatory standards, eliminating downstream compliance gaps

Audit-Ready Documentation

Complete discovery documentation that seamlessly transitions to clinical development